All In Biotech

NDA 202008 · Avid Radiopharms INC

Amyvid

Florbetapir F-18 · Intravenous · Radioactive Diagnostic Agent

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Jun 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Apr 6, 2012

Approved uses

2

Original approval plus efficacy supplements

Registered trials

59

7 Phase 3, 6 recruiting

FAERS reports

115

23 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 11, 2025.

AMYVID is indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer's disease (AD) and other causes of cognitive decline Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products AMYVID is a radioactive diagnostic drug indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer's disease (AD) and other causes of cognitive decline Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products ( 1 )

Mechanism: Florbetapir F 18 binds to amyloid beta plaques and the F 18 isotope produces a positron signal that is detected by a PET scanner. In in vitro binding studies using postmortem human brain homogenates containing amyloid beta plaques, the dissociation constant (Kd) for florbetapir was 3.7 ± 0.3 nM. The binding of florbetapir F 18 to amyloid beta aggregates was demonstrated in postmortem human brain sections using autoradiographic methods, thioflavin S and traditional silver staining correlation studies as well as immunohistochemistry (monoclonal antibody to amyloid beta) correlation studies....

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 23, 2025 Supplement 46 · Efficacy LabelLetter
  • Apr 6, 2012 Original approval · Type 1 - New Molecular Entity · priority review NovelReviewLabelLetter
4 products under this application
  • AMYVID · FLORBETAPIR F-18 10-50ML (13.5-51mCi/ML) · SOLUTION, INTRAVENOUS · Prescription
  • AMYVID · FLORBETAPIR F-18 10ML (13.5-51mCi/ML) · SOLUTION, INTRAVENOUS · Discontinued
  • AMYVID · FLORBETAPIR F-18 10-100ML (13.5-51mCi/ML) · SOLUTION, INTRAVENOUS · Prescription
  • AMYVID · FLORBETAPIR F-18 10-30ML (13.5-51mCi/ML) · SOLUTION, INTRAVENOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Florbetapir F-18" as an intervention, any sponsor and status, largest first.

All 59 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • amyloid related imaging abnormality-oedema/effusion28
  • amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits27
  • headache14
  • superficial siderosis of central nervous system9
  • injection site pain7
  • chest pain4
  • fall4
  • fatigue4
  • nausea4
  • balance disorder3
  • burning sensation3
  • confusional state3

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20131
20142
201515
20167
20175
20183
20192
20202
20212
20223
202345
20246
202518
20264

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6 on PubMed

Sponsor: Avid Radiopharms INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.